<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds</h1>

    <table>
      <tr><th>Ticker</th><td>EVGN</td></tr>
      <tr><th>Float</th><td>8.6 M</td></tr>
      <tr><th>IO</th><td>2.77%</td></tr>
      <tr><th>MC</th><td>9.6 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Evogene (Nasdaq/TASE: EVGN) entered a warrant inducement agreement with an existing institutional investor to induce immediate exercise of August 2024 Series A and Series B warrants (each to purchase up to 1,692,308 ordinary shares) at a reduced exercise price of $1.00, generating approximately $3.4 million in gross proceeds (before fees and expenses). In a private placement, the investor will receive new Series A-1 warrants (to purchase up to 2,538,462 shares) and Series B-1 warrants (to purchase up to 2,538,462 shares) with an exercise price of $1.25, immediately exercisable. Series A-1 expires five years from issuance; Series B-1 expires 18 months from issuance. Closing is expected on or about Feb. 11, 2026, subject to customary conditions. A.G.P./Alliance Global Partners is sole financial advisor. Proceeds are intended for working capital and general corporate purposes. The new warrants and underlying shares were offered in a private placement to accredited investors and Evogene plans to file a registration statement covering resale of shares issuable upon exercise.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Immediate cash infusion of approximately $3.4 million before fees and expenses</li><li>Existing investor commits to exercise warrants, indicating investor support</li><li>New warrants are immediately exercisable, providing potential additional future proceeds at $1.25 per share</li><li>Company intends to file a registration statement to enable resale of shares issuable upon exercise</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Dilution risk: immediate issuance of shares upon exercise and a large number of additional warrants (potentially up to 5,076,924 shares) outstanding</li><li>Existing warrants exercised at a reduced $1.00 price, which may reflect downward pressure on valuation</li><li>Net proceeds will be reduced by financial advisor fees and transaction expenses</li><li>New warrants and underlying shares are unregistered at issuance and subject to resale restrictions until registration</li></ul>
    </div>

    <div class="section">
      <a href="https://www.prnewswire.com/news-releases/evogene-announces-a-warrant-inducement-transaction-for-approximately-3-4-million-of-gross-proceeds-302684130.html" target="_blank">Original Article</a>
    </div>

    <div class="small">EVGN â€¢ TradersLink AI News</div>
  </div>
</body>
</html>